03.03.2020 – Medartis Holding AG

Medartis reports good sales growth above market levels in 2019

Medartis Holding AG / Key word(s): Annual Results
Medartis reports good sales growth above market levels in 2019

03-March-2020 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.


Medartis Holding AG
Hochbergerstrasse 60E
CH-4057 Basel


Medartis reports good sales growth above market levels in 2019

Basel, Switzerland, 3 March 2020 - Medartis Holding AG (SIX: MED), a leading
manufacturer and provider of medical devices for surgical fixation of bone
fractures, reported a solid sales increase of 10% in local currencies for
2019, once again exceeding market growth. EBITDA increased to CHF 20.3
million and the adjusted EBITDA margin was 15%. For 2020, Medartis expects
unchanged sales growth of 10% in local currencies with an adjusted EBITDA
margin of 15%.

Today, Medartis will hold a conference (in German) for the media, analysts
and investors at Hotel Widder, Rennweg 7, Zurich, at 9:30 CET, as well as a
telephone conference (in English) at 14:00 CET.

    CHFm          2018       2018       2019       2019      Change
               (reported) (adjusted) (reported) (adjusted) (adjusted)
    Sales        121.3      121.3      130.1      130.1    7%/10% LC
    Gross        101.0     101.2(1)    111.3     110.6(2)      9%
    Opex          95.0     91.9(1)     103.9     103.6(3)     13%
    Operating     6.1       9.3(1)      7.4       7.0(4)      -25%
    EBIT           5%         8%         6%         5%        -3pp
    EBITDA        14.4     17.6(1)      20.3     20.0(4)      14%
    EBITDA        12%        15%        16%        15%        0pp

    Headcount     561        561        609        609         9%
(1) Excluding capital market-related costs (IPO) of CHF 3.2 million.

(2) Excluding positive effect from pension fund plan amendment of CHF 0.7

(3) Excluding a provision for possible price and commission agreements in
Brazil of CHF 3.0 million and excluding positive effect from pension fund
plan amendment of CHF 2.7 million.

(4) Excluding a provision for possible price and commission agreements in
Brazil of CHF 3.0 million and excluding positive effect from pension fund
plan amendment of CHF 3.4 million.

In the 2019 financial year, Medartis reported sales of CHF 130.1 million.
This corresponds to solid year-on-year growth of 10% in local currencies,
compared with 8% in the first half of 2019, and is within the upper range of
the forecasted 8-10% growth rate. On a CHF basis, sales in 2019 rose by 7%,
which in particular reflects the exchange rate developments against the
euro, the Brazilian real and the Australian dollar.

Medartis' subsidiaries in the core European, Australian and US markets
continued to develop significantly above market levels, while development in
the distributor markets was mixed. In terms of products, hand and wrist,
which are the strongest sales lines, continued their previous growth path.
The Lower Extremities segment experienced dynamic but less-than-expected

In line with the company's growth strategy, adjusted operating expenses rose
by 13% in the 2019 financial year. Important areas of investment included
preparations for the entry into force of the EU Medical Device Regulation
(MDR), enhanced training initiatives with Medartis' scientific partner
International Bone Research Association (IBRA), build-up investments in
Japan and China, the expansion of the supply chain as well as the
recruitment of additional employees. Headcount increased from 561 at the end
of 2018 to 609 at year-end 2019.

Profitability at the EBITDA level increased from CHF 14.4 million in the
previous year to CHF 20.3 million in the 2019 financial year, including an
effect of CHF 3.6 million resulting from the first-time application of the
IFRS 16 accounting standard.

Adjusted for the CHF 3.0 million provision for possible price and commission
agreements at former distributor Extera in Brazil announced in December
2019, as well as a positive effect of CHF 3.4 million arising from pension
fund plan amendment, EBITDA for 2019 was CHF 20.0 million. This compares
with an EBITDA adjusted for CHF 3.2 million in IPO costs of CHF 17.6 million
in 2018. The reported EBITDA margin was 16% versus 12% in 2018. The adjusted
EBITDA margin remained unchanged at 15% compared to 2018.

EBIT in 2019 was CHF 7.4 million versus CHF 6.1 million one year ago, and
net profit was CHF 2.1 million compared to CHF 4.2 million in 2018. Cash
flow from operating activities was CHF 8.1 million compared to CHF 6.5
million in 2018.

Development by region

                         EMEA APAC LATAM North America Total
    Sales, CHFm
    2019                 70.3 23.7 14.4      21.7      130.1
    2018                 66.4 22.8 12.9      19.3      121.3
    Growth, %
    in CHF                6%   4%   12%       12%         7%
    in local currencies   9%   9%   16%       11%        10%
Medartis' biggest region, EMEA, recorded sales of CHF 70.3 million in 2019,
which corresponds to growth of 9% in local currencies compared with 2018.
The subsidiaries in the UK, France and Poland reported dynamic growth above
expectations, while the other subsidiaries developed solidly. The important
distributor markets Italy and Spain remained below expectations, which is in
part attributable to more cautious investment behavior in light of the new
MDR, but reported improved trends in the second half of the year. The
Netherlands, a leading European market for sterile products, achieved
dynamic growth supported by investments made by the distributor. Medartis is
well prepared for the MDR when it comes into force at the beginning of May

In North America, sales experienced strong growth of 11% in local currency,
increasing to CHF 21.7 million. This is mainly attributable to the hand,
wrist and elbow segments. An innovative wrist plate developed specifically
for the US market was introduced in the fourth quarter of 2019, meeting with
very good customer feedback. Thanks to various initiatives currently
underway to further build up the US business, the subsidiary continued to
see significantly above-market growth, but has not yet achieved the
envisioned growth momentum.

Sales in APAC increased 9% in local currencies to CHF 23.7 million. The
subsidiary in Australia, Medartis' strongest sales market in the region,
recorded solid growth with a strong increase in case numbers despite a
nation-wide reduction to all reimbursements in the health care system of 7%.
The new subsidiary in Japan, which began operations in the Lower Extremities
segment at the end of 2018, significantly increased sales in the second half
of the year and developed according to plan. The distributor business in
Japan in Upper Extremities did not meet expectations despite an improved
second half of the year. In contrast, the two larger distributors in South
Korea and Thailand grew dynamically. As expected, the new subsidiary in
China obtained product authorization in 2019 and will begin to develop the
market in 2020.

In LATAM, Medartis reported sales of CHF 14.4 million, which corresponds to
growth of 16% in local currencies. In a persistently challenging market
environment, the subsidiary in Brazil achieved dynamic growth exceeding that
of the previous year (on an organic basis). In contrast, the subsidiary in
Mexico was below expectations. In terms of distributor markets, Chile also
grew dynamically, and Columbia further expanded its sales as a result of a
strong rise in hand and wrist cases.

Development of business segments

                            Upper       Lower    CMF and Total
                         Extremities Extremities Others
    Sales, CHFm
    2019                    92.6        18.3      19.2   130.1
    2018                    87.2        16.4      17.8   121.3
    Growth, %
    in CHF                   6%          12%       8%       7%
    in local currencies      9%          16%       10%     10%
Upper Extremities, Medartis' largest business segment, recorded a sales
increase of 9% to CHF 92.6 million in local currencies in the 2019 financial
year. Medartis gained further market share in many core markets with an
established market position in the hand and wrist segment. The segments
wrist, which is the strongest sales segment, and elbow saw continued strong
growth in local currencies, while the hand segment reported solid growth.
Sales growth in the shoulder segment almost doubled, at a low level,
compared with 2018. In mid-2020, Medartis will complement the existing
plates and screws portfolio with the introduction of a forearm fracture
system and an innovative clavicle system to the market.

Lower Extremities, Medartis' youngest business segment, recorded sales of
CHF 18.3 million in 2019, which corresponds to growth in local currencies of
16% and was below expectations. With a view to further rounding out the
plates and screws portfolio, and as a foundation for more dynamic growth,
additional innovative systems for corrections in the mid- and hindfoot and
for fractures of the lower tibia and fibula are planned to be introduced to
the market in mid-2020.

The CMF and Others segment, which comprises solutions for the
craniomaxillofacial region as well as instruments and containers, recorded
sales growth in local currencies of 10% to CHF 19.2 million in the 2019
financial year. Medartis experienced above-market growth in the CMF segment.
The introduction of a new generation of the CMF product line is planned for
April 2020.


Since its founding in 1997, Medartis has stood for innovative strength and
technological leadership. Building on these strengths, the sales focus,
market orientation, especially in the US, and the speed in innovation are to
be strengthened in line with the existing growth strategy.

- Sales focus: Targeted focus on regional market requirements by anchoring
the EMEA, North America and LATAM/APAC regions at the executive management

- US business: Building and expanding the US business as a top priority
through recruitment of a new leadership team, expansion of sales (direct and
via distributors) and build-up of US-focused product development

- Innovative strength: Accelerated expansion of innovation pipeline by
shortening development times as well as through partnerships and M&A

- Rollout of expanded range of cannulated compression screws scheduled for
June 2020 after shortened development time of five months; a total of six
innovations are planned to be brought to the market in 2020

- Two projects for complementary technologies and indications being
implemented with partners

- M&A longlist with over 200 potential targets, five due-diligence reviews

The organizational changes necessary to implement this program have been
initiated and will be completed within the current year. Over the medium
term, Medartis wants to achieve annual sales growth of over 15% in local
currencies with a gradual increase in the adjusted EBITDA margin.

For 2020, as the program is being implemented and in light of the mild
winter with lower case numbers, Medartis expects unchanged sales growth of
10% in local currencies with an adjusted EBITDA margin of 15% (barring
unforeseen circumstances).

Christoph Brönnimann, CEO Medartis: "We achieved good growth above the
market in 2019, but we have not yet met our own expectations. Medartis
stands for innovative strength, and the next step is now to further increase
our speed in innovation and efficiency in sales. Another key focus is the
accelerated building of our business in the US, the biggest market for our
industry. 2020 will be an important year for strengthening our organization,
where we will also continue to invest while bringing innovations to the
market. This positions us well for further substantial growth over the
medium term and a gradual increase in profitability over the coming years."

Documents 2019 full-year results
The following documents pertaining to the 2019 full-year results are
available online:

Press release:
Press release 2019 results

Presentation 2019 results

Annual Report:
2019 Annual Report

Media, analyst and investor conference in Zurich (in German)
Date: Tuesday, 3 March 2020
Time: 9:30 CET
Location: Hotel Widder, Rennweg 7, Zurich
Speakers: Christoph Brönnimann, CEO; Dominique Leutwyler, CFO

Telephone conference for media, analysts and investors (in English)
Date: Tuesday, 3 March 2020
Time: 14:00 CET
Speakers: Christoph Brönnimann, CEO; Dominique Leutwyler, CFO

Join with PC, Mac, Linux, iOS or Android:

Dial-in numbers by telephone:
Switzerland +41 31 528 0988
UK +44 203 051 2874
US +1 669 900 6833
For other international numbers go to: https://medartis.zoom.us/u/acjCfpd2Sy

When dialling in by telephone, questions may be asked during the call via
e-mail to corporate.communication@medartis.com.

Meeting ID: 991 600 792

Financial calendar
17 April 2020 Annual General Meeting
18 August 2020 Publication of 2020 half-year results
9 March 2021 Publication of 2020 full-year results

Patrick Christ
Head Corporate Services
Medartis Holding AG
Phone: +41 61 633 34 70

About Medartis
Founded in 1997 and headquartered in Basel, Switzerland, Medartis is one of
the world's leading manufacturers and providers of medical devices for
surgical fixation of bone fractures for upper and lower extremities as well
as for the craniomaxillofacial region. Medartis employs over 600 individuals
across its 13 locations, with products offered in over 50 countries
globally. Medartis is committed to providing surgeons and operating theater
personnel with the most innovative titanium implants and instruments as well
as best in class service. For more information, please visit

This communication does not constitute an offer or invitation to subscribe
for or purchase any securities of Medartis Holding AG. This publication may
contain certain forward-looking statements and assessments or intentions
concerning the company and its business. Such statements involve certain
risks, uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of the company to be
materially different from those expressed or implied by such statements.
Readers should therefore not place reliance on these statements,
particularly not in connection with any contract or investment decision. The
company disclaims any obligation to update these forward-looking statements,
assessments or intentions. Further, neither the company nor any of its
directors, officers, employees, agents, counsel or advisers nor any other
person makes any representation or warranty, express or implied, as to, and
accordingly no reliance should be placed on, the accuracy or completeness of
the information contained herein or of the views given or implied.


End of ad hoc announcement